1. Pink Sheet
  2. >>Geography
  3. >>Europe

Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings

 
• By Neena Brizmohun

EU marketing authorization applications have been submitted for a number of new drugs, including Eli Lilly’s donanemab, Italfarmaco's givinostat and Arcturus Therapeutics/CSL’s ARCT-154.

Alzheimer's patient
Donanemab was shown to significantly slow cognitive and functional decline in people with early symptomatic Alzheimer's disease • Source: Shutterstock

Donanemab, Eli Lilly’s investigational treatment for Alzheimer's disease, and Arcturus Therapeutics/CSL’s COVID-19 vaccine candidate, ARCT-154, are among the latest products that the European Medicines Agency has started reviewing for potential pan-EU marketing authorization.

Donanemab is an anti-amyloid therapy for slowing disease progression in patients with early symptomatic Alzheimer’s disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.